{"DataElement":{"publicId":"7334376","version":"1","preferredName":"Kaposi Sarcoma Stage Immune System Grouping Status","preferredDefinition":"Text terms that represent the status of the Kaposi sarcoma stage immune system grouping.","longName":"IMM_RSORRES","context":"AMC","contextVersion":"1","DataElementConcept":{"publicId":"2639678","version":"1","preferredName":"Kaposi Sarcoma Stage Immune System Grouping","preferredDefinition":"information relating to the immune system and the staging (the extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body) of Kaposi Sarcoma (a malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells).","longName":"KS_ST_IMMSYS_GP","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2639672","version":"1","preferredName":"Kaposi Sarcoma Stage","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C9087:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"30C2CE6B-5238-31E7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-18","modifiedBy":"ONEDATA","dateModified":"2007-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2639676","version":"1","preferredName":"Immune System Grouping","preferredDefinition":"includes the thymus, spleen, lymphatic system, bone marrow, tonsils, and Peyer's patches, and the migratory cells these organs generate: lymphocytes, granulocytes, and cells of the monocyte- macrophage type.:Grouping; a system for classifying things into groups; the activity of putting things together in groups.","longName":"C12735:C25523","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune System","conceptCode":"C12735","definition":"The complex group of organs like thymus, spleen, tonsils, lymphatic system, hematopoetic system and cells like lymphocytes, granulocytes, monocytes and macrophages that defends the body against infection or disease. It consists of a complex interrelated cellular, molecular and genetic component.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grouping","conceptCode":"C25523","definition":"A system for classifying things into groups or the activity of putting things together in groups.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"30C409E4-D4E7-3800-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-18","modifiedBy":"ONEDATA","dateModified":"2007-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"30C409E4-D4F8-3800-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7334367","version":"1","preferredName":"Kaposi Sarcoma Immune System Status","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS)._The complex group of organs like thymus, spleen, tonsils, lymphatic system, hematopoetic system and cells like lymphocytes, granulocytes, monocytes and macrophages that defends the body against infection or disease. It consists of a complex interrelated cellular, molecular and genetic component._A condition or state at a particular time.","longName":"7334367v1.0","context":"AMC","contextVersion":"1","type":"Enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CD4 cells less than (<) 200/uL","valueDescription":"CD4 cells less than (<) 200/uL","ValueMeaning":{"publicId":"7379118","version":"1","preferredName":"CD4 cells less than (<) 200/uL","longName":"7379118","preferredDefinition":"CD4 cells less than (<) 200/uL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC2145FE-0A42-1DEE-E053-4EBD850A9DC5","latestVersionIndicator":"Yes","beginDate":"2020-08-05","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-08-05","modifiedBy":"ONEDATA","dateModified":"2020-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC2145FE-0A5B-1DEE-E053-4EBD850A9DC5","beginDate":"2020-08-05","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-08-05","modifiedBy":"ONEDATA","dateModified":"2020-08-05","deletedIndicator":"No"},{"value":"CD4 cells greater than or equal to (>=) 200/uL","valueDescription":"CD4 cells greater than or equal to (>=) 200/uL","ValueMeaning":{"publicId":"7379119","version":"1","preferredName":"CD4 cells greater than or equal to (>=) 200/uL","longName":"7379119","preferredDefinition":"CD4 cells greater than or equal to (>=) 200/uL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC2145FE-0A65-1DEE-E053-4EBD850A9DC5","latestVersionIndicator":"Yes","beginDate":"2020-08-05","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-08-05","modifiedBy":"ONEDATA","dateModified":"2020-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC2145FE-0A7E-1DEE-E053-4EBD850A9DC5","beginDate":"2020-08-05","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-08-05","modifiedBy":"ONEDATA","dateModified":"2020-08-05","deletedIndicator":"No"},{"value":"U","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A84A67F1-365A-7512-E053-4EBD850A78F2","beginDate":"2007-05-31","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-06-17","modifiedBy":"ONEDATA","dateModified":"2020-06-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7379116","version":"1","preferredName":"Kaposi Sarcoma Immune System Status","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).:The complex group of organs like thymus, spleen, tonsils, lymphatic system, hematopoetic system and cells like lymphocytes, granulocytes, monocytes and macrophages that defends the body against infection or disease. It consists of a complex interrelated cellular, molecular and genetic component.:A condition or state at a particular time.","longName":"C9087:C12735:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Immune System","conceptCode":"C12735","definition":"The complex group of organs like thymus, spleen, tonsils, lymphatic system, hematopoetic system and cells like lymphocytes, granulocytes, monocytes and macrophages that defends the body against infection or disease. It consists of a complex interrelated cellular, molecular and genetic component.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC2145FE-0A1A-1DEE-E053-4EBD850A9DC5","latestVersionIndicator":"Yes","beginDate":"2020-08-05","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-08-05","modifiedBy":"ONEDATA","dateModified":"2020-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A84A67F1-3646-7512-E053-4EBD850A78F2","latestVersionIndicator":"Yes","beginDate":"2020-06-17","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-06-17","modifiedBy":"COLLIED","dateModified":"2020-08-25","changeDescription":"Curated for AMC 107 protocol DC","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"7283431","version":"1","longName":"CRF CDEs","context":"AMC","ClassificationSchemeItems":[{"publicId":"7312662","version":"1","longName":"KS","context":"AMC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Immune system (I)","type":"Preferred Question Text","description":"Immune system (I)","url":null,"context":"AMC"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A84A7CD7-82CD-6B6D-E053-4EBD850AD475","latestVersionIndicator":"Yes","beginDate":"2020-06-17","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-06-17","modifiedBy":"COLLIED","dateModified":"2020-08-28","changeDescription":"Curated for AMC 107 protocol DC","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}